European CHMP recommends approval of extension to existing indication for niraparib
The CHMP recommends approval for use as monotherapy for maintenance treatment of adults with advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of 1st line platinum-based chemotherapy.
Source:
European Medicines Agency